drugset / Trial / NCT01265576
Study of Sorafenib With or Without VT-122 in Patients With Hepatocellular Carcinoma (HCC)
RandomizedParallel-groupQuadruple-blindTreatment
Summary
The purpose of this study is to determine if VT-122 provides a clinical benefit when added to Sorafenib in patients with advanced hepatocellular carcinoma (HCC).
Timeline
- Start
- 2010-12
- Primary completion
- 2014-02
- Completion
- 2016-04
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Etodolac | Unknown | 300 mg | Oral |
| Subject | Propranolol | Small molecule | 60 mg | Oral |
| Background | Sorafenib | Small molecule | — | — |